[HTML][HTML] Considerations in boosting COVID-19 vaccine immune responses
PR Krause, TR Fleming, R Peto, IM Longini… - The Lancet, 2021 - thelancet.com
Considerations in boosting COVID-19 vaccine immune responses - The Lancet Skip to Main
Content Advertisement The Lancet Journal This Journal Back Journal Home Online First …
Content Advertisement The Lancet Journal This Journal Back Journal Home Online First …
[HTML][HTML] The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: A systematic review and meta-analysis
K Rahmani, R Shavaleh, M Forouhi… - Frontiers in public …, 2022 - frontiersin.org
Background Vaccination, one of the most important and effective ways of preventing
infectious diseases, has recently been used to control the COVID-19 pandemic. The present …
infectious diseases, has recently been used to control the COVID-19 pandemic. The present …
[HTML][HTML] Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19–associated emergency department and urgent care encounters and …
JM Ferdinands - MMWR. Morbidity and mortality weekly report, 2022 - cdc.gov
Vaccine effectiveness (VE) against COVID-19–associated emergency department/urgent
care (ED/UC) visits and hospitalizations was higher after the third dose than after the second …
care (ED/UC) visits and hospitalizations was higher after the third dose than after the second …
[HTML][HTML] Effectiveness of a third dose of mRNA vaccines against COVID-19–associated emergency department and urgent care encounters and hospitalizations …
MG Thompson - MMWR. Morbidity and mortality weekly report, 2022 - cdc.gov
VE was significantly higher among patients who received their second mRNA COVID-19
vaccine dose< 180 days before medical encounters compared with those vaccinated≥ 180 …
vaccine dose< 180 days before medical encounters compared with those vaccinated≥ 180 …
[HTML][HTML] Duration of protection against mild and severe disease by Covid-19 vaccines
Background Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), the virus that causes coronavirus disease 2019 (Covid-19), have been used since …
2), the virus that causes coronavirus disease 2019 (Covid-19), have been used since …
[HTML][HTML] Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA vaccination in preventing COVID-19–associated emergency department and urgent care …
NP Klein - MMWR. Morbidity and mortality weekly report, 2022 - cdc.gov
Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing
COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations …
COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations …
Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study
KJ Bruxvoort, LS Sy, L Qian, BK Ackerson, Y Luo… - Bmj, 2021 - bmj.com
Objectives To evaluate the effectiveness of the mRNA-1273 vaccine against SARS-CoV-2
variants and assess its effectiveness against the delta variant by time since vaccination …
variants and assess its effectiveness against the delta variant by time since vaccination …
[HTML][HTML] Effectiveness of mRNA vaccination in preventing COVID-19–associated invasive mechanical ventilation and death—United States, March 2021–January …
MW Tenforde - MMWR. Morbidity and mortality weekly report, 2022 - cdc.gov
COVID-19 mRNA vaccines provide protection against COVID-19 hospitalization among
adults. However, how well mRNA vaccines protect against the most severe outcomes of …
adults. However, how well mRNA vaccines protect against the most severe outcomes of …
[HTML][HTML] Effectiveness of 2, 3, and 4 COVID-19 mRNA vaccine doses among immunocompetent adults during periods when SARS-CoV-2 Omicron BA. 1 and BA. 2/BA …
R Link-Gelles - MMWR. Morbidity and mortality weekly report, 2022 - cdc.gov
Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults
During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages …
During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages …
[HTML][HTML] Effectiveness of 2-dose vaccination with mRNA COVID-19 vaccines against COVID-19–associated hospitalizations among immunocompromised adults—nine …
PJ Embi - MMWR. Morbidity and Mortality Weekly Report, 2021 - cdc.gov
Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19–Associated
Hospitalizations Among Immunocompromised Adults — Nine States, January–September …
Hospitalizations Among Immunocompromised Adults — Nine States, January–September …